The DOI matches its Crossref record; 259 of the 259 references it cites were found in a registry or an index.
Clozapine versus typical neuroleptic medication for schizophrenia
Open accessAbstract
BACKGROUND: Long-term drug treatment of schizophrenia with typical antipsychotics has limitations: 25 to 33% of patients have illnesses that are treatment-resistant. Clozapine is an antipsychotic drug, which is claimed to have superior efficacy and to cause fewer motor adverse effects than typical drugs for people with treatment-resistant illnesses. Clozapine carries a significant risk of serious blood disorders, which necessitates mandatory weekly blood monitoring at least during the first months of treatment. OBJECTIVES: To evaluate the effects of clozapine compared with typical antipsychotic drugs in people with schizophrenia. SEARCH STRATEGY: For the current update of this review (March 2006) we searched the Cochrane Schizophrenia Group Trials Register. SELECTION CRITERIA: All relevant randomised clinical trials (RCTs). DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis, based on a fixed-effect model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated weighted mean differences (WMD) again based on a fixed-effect model. MAIN RESULTS: We have included 42 trials (3950 participants) in this review. Twenty-eight of the included studies are less than 13 weeks in duration, and, overall, trials were at significant risk of bias. We found no significant difference in the effects of clozapine and typical neuroleptic drugs for broad outcomes such as mortality, ability to work or suitability for discharge at the end of the study. Clinical improvements were seen more frequently in those taking clozapine (n=1119, 14 RCTs, RR 0.72 CI 0.7 to 0.8, NNT 6 CI 5 to 8). Also, participants given clozapine had fewer relapses than those on typical antipsychotic drugs (n=1303, RR 0.62 CI 0.5 to 0.8, NNT 21 CI 15 to 49). BPRS scores showed a greater reduction of symptoms in clozapine-treated patients, (n=1145, 16 RCTs, WMD -4.22 CI -5.4 to -3.1), although the data were heterogeneous (Chi(2) 0.0001, I(2) 66%). Short-term data from the SANS negative symptom scores favoured clozapine (n=196, 5 RCTs, WMD -5.92 CI -7.8 to -4.1). We found clozapine to be more acceptable in long-term treatment than conventional antipsychotic drugs (n=982, 16 RCTs, RR 0.60 CI 0.5 to 0.7, NNT 15 CI 12 to 20). Blood problems occurred more frequently in participants receiving clozapine (3.2%) compared with those given typical antipsychotics (0%) (n=1031, 13 RCTs, RR 7.09 CI 2.0 to 25.6). Clozapine participants experienced more drowsiness, hypersalivation, or temperature increase, than those given conventional neuroleptics. However, clozapine patients experienced fewer motor adverse effects (n=1433, 18 RCTs, RR 0.58 CI 0.5 to 0.7, NNT 5 CI 4 to 6).The clinical effects of clozapine were more pronounced in participants resistant to typical neuroleptics in terms of clinical improvement (n=370, 4 RCTs, RR 0.71 CI 0.6 to 0.8, NNT 4 CI 3 to 6) and symptom reduction. Thirty-four per cent of treatment-resistant participants had a clinical improvement with clozapine treatment. AUTHORS' CONCLUSIONS: Clozapine may be more effective in reducing symptoms of schizophrenia, producing clinically meaningful improvements and postponing relapse, than typical antipsychotic drugs - but data are weak and prone to bias. Participants were more satisfied with clozapine treatment than with typical neuroleptic treatment. The clinical effect of clozapine, however, is, at least in the short term, not reflected in measures of global functioning such as ability to leave the hospital and maintain an occupation. The short-term benefits of clozapine have to be weighed against the risk of adverse effects. Within the context of trials, the potentially dangerous white blood cell decline seems to be more frequent in children and adolescents and in the elderly than in young adults or people of middle-age.The existing trials have largely neglected to assess the views of participants and their families on clozapine. More community-based long-term randomised trials are needed to evaluate the efficacy of clozapine on global and social functioning as trials in special groups such as people with learning disabilities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–259 of 259
Predictors of clozapine response in schizophrenia.
Pickar, D., Owen, R., Litman, R. E., Hsiao, J., & Su, T. (1994) · PubMed · Cited by 48
Maher, B. A., Manschreck, T. C., Redmond, D., & Beaudette, S. (1996) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00066-7 · Cited by 48
Lindstr�m, L. H. (1989) · Psychopharmacology · doi:10.1007/bf00442567 · Cited by 48
Reducing the Risk for Suicide in Schizophrenia and Affective Disorders
Meltzer, H. Y., & Baldessarini, R. J. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0920 · Cited by 48
Bürki, H. R. (1979) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(79)90127-x · Cited by 47
Moresco, R. M., Cavallaro, R., Messa, C., Bravi, D., Gobbo, C. L., Galli, L., Lucignani, G., Colombo, C., Rizzo, G., Velonà, I., et al. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800306 · Cited by 46
Clozapine effects on tardive dyskinesia.
Ja, L., Saltz, B. L., Johns, C. A., Pollack, S. Z., & Kane, J. M. (1989) · PubMed · Cited by 43
The effect of clozapine on self-injurious behavior
Hammock, R. G., Schroeder, S. R., & LeVine, W. R. (1995) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02178191 · Cited by 41
Does eosinophilia predict clozapine induced neutropenia?
Hummer, M., Sperner‐Unterweger, B., Kurz, M., Fleischhacker, W. W., Falk, M. J., Kemmler, G., & OBERBAUER, H. (1996) · Psychopharmacology · doi:10.1007/bf02245622 · Cited by 41
Blum, A., & Mauruschat, W. (1972) · Pharmacopsychiatry · doi:10.1055/s-0028-1094343 · Cited by 41
Predictors of response to clozapine therapy
Honigfeld, G., & Patin, J. R. (1989) · Psychopharmacology · doi:10.1007/bf00442562 · Cited by 40
Rosenheck, R. A., Cramer, J. A., Xu, W., Grabowski, J., Douyon, R., Thomas, J. V., Henderson, W., & Charney, D. S. (1998) · Europe PMC (PubMed Central) · Cited by 39
Atypical antipsychotics in the EPS-vulnerable patient
Friedman, J. H. (2002) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00111-7 · Cited by 39
Stryjer, R., Strous, R. D., Bar, F., Shaked, G., Shiloh, R., Rozencwaig, S., Grupper, D., Buchman, N., Kotler, M., Rabey, J. M., et al. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.595 · Cited by 39
Möller, H. J., Riedel, M. J., Müller, N., Fischer, W., & Kohnen, R. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832683 · Cited by 38
Clozapine response in treatment-refractory first-episode schizophrenia
Szymanski, S., Masiar, S. J., Mayerhoff, D. I., Loebel, A., Geisler, S., Pollack, S. Z., Kane, J. M., & Lieberman, J. A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91259-9 · Cited by 37
Blood biogenic amines during clozapine treatment of early-onset schizophrenia
Schulz, E., Fleischhaker, C., Clement, H. ‐., & Remschmidt, H. (1997) · Journal of Neural Transmission · doi:10.1007/bf01273320 · Cited by 37
Clozapine in the Treatment of Newly Admitted Schizophrenic Patients A Pilot Study
Chouinard, G., & Annable, L. (1976) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1976.tb02407.x · Cited by 37
Clozapine maintenance therapy in schizophrenia
Gaszner, P., & Makkos, Z. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.011 · Cited by 36
Baymiller, S. P., Ball, P. M., McMahon, R. P., & Buchanan, R. W. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00158-5 · Cited by 35
Agelink, M. W., Malessa, R., Kamcili, E., Zeit, T., Lemmer, W., Bertling, R., & Klieser, E. (1998) · Neuropsychobiology · doi:10.1159/000026512 · Cited by 34
Predictive Value of Eosinophilia for Neutropenia During Clozapine Treatment
Ames, D., Wirshing, W. C., Baker, R. W., Umbricht, D., Sun, A., Carter, J., Schooler, N. R., Kane, J. M., & Marder, S. R. (1996) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v57n1205 · Cited by 33
Edwards, J., Cocks, J., Burnett, P., Maud, D., Wong, L., Yuen, H. P., Harrigan, S., Herrmann-Doig, T., Murphy, B., Wade, D., et al. (2011) · Schizophrenia Research and Treatment · doi:10.1155/2011/394896 · Cited by 33
Schulz, E., Fleischhaker, C., & Remschmidt, H. (1996) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1996.6.119 · Cited by 33
Jacoby, M. G., & Greaves, D. (1978) · BMJ · doi:10.1136/bmj.2.6138.705-a · Cited by 33
Clinical and Psychopharmacologic Factors Influencing Family Burden in Refractory Schizophrenia
Rosenheck, R. A., Cramer, J. A., Jurgis, G., PERLICK, D. A., Xu, W., Thomas, J., Henderson, W., & Charney, D. S. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0913 · Cited by 31
Is Clozapine Safe in the Elderly?
Herst, L., & Powell, G. (1997) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679709073852 · Cited by 31
Klieser, E., Strauß, W. H., & Lemmer, W. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05836.x · Cited by 30
Clozapine for tardive dyskinesia in adolescents
Levkovitch, Y., Kronenberg, J., Kayser, N., Zvyagelski, M., Gaoni, B., & Gadoth, N. (1995) · Brain and Development · doi:10.1016/0387-7604(95)00034-9 · Cited by 28
Deficits in language-mediated mental operations in patients with schizophrenia
Wexler, B. E., Donegan, N. H., Stevens, A. A., & Jacob, S. A. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00194-3 · Cited by 27
Does patient education enhance compliance with clozapine? A preliminary investigation
Gray, R. J. (2000) · Journal of Psychiatric and Mental Health Nursing · doi:10.1046/j.1365-2850.2000.00299.x · Cited by 27
[Results of treatment with clozapine in schizophrenic adolescents].
Siefen, G., & Remschmidt, H. (1986) · PubMed · Cited by 27
Clozapine Withdrawal: Serotonergic or Dopaminergic Mechanisms?
Meltzer, H. Y. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200094013 · Cited by 26
Hospital Days in Clozapine-Treated Patients
Dickson, R. A., Dalby, J. T., Williams, R., & Warden, S. J. (1998) · The Canadian Journal of Psychiatry · doi:10.1177/070674379804300911 · Cited by 25
A Clinical Study of Clozapine Treatment and Predictors of Response in a Canadian Sample
William, G., MacEwan, G. W., Kopala, L. C., Altman, S., Chisholm-Hay, S., Singh, K., Geoffrey, N. S., Ehmann, T. S., Ganesan, S., & Lang, M. (1995) · The Canadian Journal of Psychiatry · doi:10.1177/070674379504000409 · Cited by 22
de León, J., DÍAZ, F. J., Josiassen, R. C., & Simpson, G. M. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0505-2 · Cited by 21
Kahn, R., Davidson, M., Siever, L. J., Sevy, S. M., & Davis, K. L. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91236-x · Cited by 21
Hemphill, R. E., Fd, P., & Zabow, T. (1975) · PubMed · Cited by 21
Augmentation of clozapine partial responders with conventional antipsychotics
Rajarethinam, R., Gilani, S., Tancer, M. E., & DeQuardo, J. R. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00293-1 · Cited by 20
Pickar, D., & Bartko, J. J. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1133 · Cited by 20
Rosenheck, R. A., Doyle, J., LESLIE, D. L., & FONTANA, A. F. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006994 · Cited by 19
Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia.
Diamond, B. I., & Borison, R. L. (1986) · PubMed · Cited by 19
[Multifocal psychopharmaceutic testing ("Multihospital trial")].
Fischer-Cornelssen, K. A., Ferner, U., & Steiner, H. (1974) · PubMed · Cited by 17
Clozapine Treatment of Schizophrenia
Pickar, D. (1995) · JAMA · doi:10.1001/jama.1995.03530120073044 · Cited by 16
The current status of clozapine.
Shopsin, B., & Feiner, N. F. (1983) · PubMed · Cited by 16
Efficacy of clozapine versus haloperidol in a long-term clinical trial
Kane, J. M., Schooler, N., Marder, S. R., Wirshing, W. C., Ames, D., Umbricht, D., Safferman, A. Z., Baker, R., & Ganguli, R. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(96)85427-2 · Cited by 12
Dose related response to clozapine in a state psychiatric hospital population: A naturalistic study
Gordon, B. J., & Milke, D. J. (1996) · Psychiatric Quarterly · doi:10.1007/bf02244276 · Cited by 12
Rimón, R., Kuoppasalmi, K. I., Naukkarjnen, H., Lang, S., Sandqvist, A., & Leinonen, E. V. J. (1994) · Nordic Journal of Psychiatry · doi:10.3109/08039489409081367 · Cited by 12
Edwards, J., Wong, L. L.-K., Burnett, P., Harrigan, S., McGorry, P. D., Wade, D., Murphy, B., Drew, L., & Albiston, D. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80279-7 · Cited by 11
Efficacy of medium-dose clozapine for treatment-resistant schizophrenia
Kurz, M., Hummer, M., Kurzthaler, I., OBERBAUER, H., & Fleischhacker, W. W. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1690b · Cited by 11
Clozapine as a treatment tool: only in resistant schizophrenic patients?
Cassano, G., Ciapparelli, A., & Villa, M. A. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83578-x · Cited by 9
[Clozapine in long-term therapy of chronic schizophrenia].
Gross, H., Langner, E., & Pfolz, H. (1974) · PubMed · Cited by 8
Pérez, R. S., González‐Blanch, C., Sierra‐Biddle, D., ́nez, I. M., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80508-x · Cited by 7
Jackson, C. T., Covell, N. H., & Essock, S. M. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007073 · Cited by 4
A randomized, double-blind trial of the efficacy and cost-effectiveness of clozapine
Rosenheck, R. A., Charney, D. S., Cramer, J. A., Xu, W., & Thomas, J. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)82537-6 · Cited by 4
Diphenhydramine for clozapine-induced salivation at various dosage levels
He, X. (1997) · Cited by 4
The effects of risperidone and clozapine to patients with schizophrenia's life quality.
Minghu, D. (2003) · Sichuan Mental Health · Cited by 4
Spontaneous dyskinesia in schizophrenia
Fenton, W. S., Wyatt, R. J., & McGlashan, T. H. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(95)95637-o · Cited by 3
Huiyu, J. (2001) · Sichuan Mental Health · Cited by 2
Cited by
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Metadata
- Authors
- Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-01-21
- Volume
- 2010
- Issue
- 1
- Pages
- CD000059-CD000059
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2135182273
- Cited by
- 329
- References
- 259
- FWCI
- 14.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.